Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • 11/14/22
Spero Therapeutics Announces Third Quarter 2022 Operating Results and Provides Business UpdateGlobeNewsWire • 11/14/22
Spero Therapeutics Announces Closing of Exclusive License Agreement with GSK for Tebipenem HBrGlobeNewsWire • 11/08/22
Spero Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results on Monday, November 14, 2022GlobeNewsWire • 11/07/22
Spero Therapeutics, Inc. (SPRO) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 11/02/22
These Were The Five Best And Worst Performing Healthcare Stocks In September 202224/7 Wall Street • 10/17/22
Spero Therapeutics to Host Virtual R&D Event on Non-Tuberculous Mycobacterial Pulmonary Disease and the SPR720 ProgramGlobeNewsWire • 10/03/22
Spero Therapeutics: The GlaxoSmithKline-Deal Changes Everything And Protects Shareholder ValueSeeking Alpha • 10/03/22
GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBrGlobeNewsWire • 09/22/22
Spero Therapeutics Announces Appointment of Kamal Hamed, MD, MPH, MBA, as Chief Medical OfficerGlobeNewsWire • 09/15/22
Spero Therapeutics Provides Tebipenem HBr Program Update Following Type A Meeting with the U.S. Food and Drug AdministrationGlobeNewsWire • 09/06/22
Spero Therapeutics, Inc. (SPRO) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 08/25/22
Spero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/11/22